- Home
- CSTL vs HYMC Comparison
CSTL vs HYMC Comparison
Compare CSTL & HYMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSTL | HYMC |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 661.7M | 648.5M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | CSTL | HYMC |
|---|---|---|
| Price | $38.83 | $11.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $38.67 | N/A |
| AVG Volume (30 Days) | 439.7K | ★ 1.6M |
| Earning Date | 11-03-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $343,530,000.00 | N/A |
| Revenue This Year | $1.69 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.15 | N/A |
| 52 Week Low | $14.59 | $1.99 |
| 52 Week High | $40.61 | $12.50 |
Technical Indicators
Market Signals| Indicator | CSTL | HYMC |
|---|---|---|
| Relative Strength Index (RSI) | 71.92 | 65.39 |
| Support Level | $38.69 | $11.10 |
| Resistance Level | $40.54 | $12.50 |
| Average True Range (ATR) | 1.58 | 0.88 |
| MACD | -0.18 | 0.09 |
| Stochastic Oscillator | 75.59 | 68.73 |
Price Performance
Historical ComparisonAbout CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About HYMC Hycroft Mining Holding Corporation
Hycroft Mining Holding Corp is a gold and silver producer. Its operating mine, the Hycroft Mine, is an open-pit heap leach operation located approximately fifty four miles west of Winnemucca, Nevada.